IM Cannabis Q1 2025 Earnings Report

IM Cannabis EPS Results

• Actual EPS: $0.06
• Consensus EPS: -$0.25
• Beat/Miss: Beat by +$0.31
• One Year Ago EPS: N/A

IM Cannabis Revenue Results

• Actual Revenue: $8.69 million
• Expected Revenue: $11.45 million
• Beat/Miss: Missed by -$2.77 million
• YoY Revenue Growth: N/A

IM Cannabis Announcement Details

• Quarter: Q1 2025
• Date: 5/15/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, May 15, 2025
• Conference Call Time: 9:00AM ET

IM Cannabis (NASDAQ:IMCC) Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards. IM Cannabis invests in ongoing scientific research and development to advance proprietary extraction techniques and novel dosage forms, with an emphasis on patient safety, reproducibility and therapeutic efficacy. These efforts support both internal clinical initiatives and potential collaborations with academic and pharmaceutical partners.

Since its founding in 2018, IM Cannabis has pursued domestic and international market expansion through supply agreements and export licenses. The company serves Israel’s growing medical cannabis patient base and has secured partnerships to facilitate exports to regulated markets, including Europe and Australia. IM Cannabis is led by an experienced management team with backgrounds in pharmaceutical development, agriculture technology and regulatory affairs, and trades on the Nasdaq Capital Market under the ticker IMCC.

IM Cannabis Q1 2025 Earnings Call Transcript

Key Takeaways

• In Q1 2025 the group delivered its first net profit of $200k and turned adjusted EBITDA to a $600k profit, compared to a $2.2M loss in Q1 2024, driven by an 87% increase in gross margin.
• Revenue from Germany surged 569% year-over-year, accounting for 62% of total sales as 12 new strains launched in the quarter contributed €3M (39%) of cannabis flower sales.
• Israeli operations saw a 66% revenue decline versus Q1 2024 due to a strategic shift to Germany and supply delays, although cost-cutting measures supported margin improvement.
• Operating expenses were cut 56% year-over-year, with selling and marketing down 44% and G&A down 14%, driving the operating expense ratio from 77% to 26% and enhancing overall efficiency.
• Cash and equivalents rose to $1.4M, total assets increased 15% to $44.9M, and the company plans to finance operations through working capital, existing credit facilities, and potential new capital sources.

Presentation

[Operator]

Good morning and welcome to IM Cannabis's first quarter 2025 earnings conference call. Today's conference call is being recorded. At this time, I would like to turn the conference over to Anna Taranko of Investor and Public Relations. Anna?

[Anna Taranko, Head of Investor Relations at IM Cannabis]

Good morning and thank you, operator. Joining me for today's call are IM Cannabis Chief Executive Officer Oren Shuster and Chief Financial Officer Uri Birenberg. The earnings and press release that accompanies this call is available on the Investor Relations section of our website at investors.imcannabis.com. Today's call will include estimates and other forward-looking information and statements, including statements concerning future results of operations, economic conditions, and anticipated courses of action, and are based on assumptions, expectations, estimates, and projections as of the date hereof. This information may involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences are described in detail in the company's most recent filings available on SEDAR+ www.sedarplus.ca and EDGAR at www.sec.gov. Furthermore, certain non-IFRS measures will be referred to during this call.

[Anna Taranko, Head of Investor Relations at IM Cannabis]

The term non-IFRS Adjusted EBITDA loss or non-IFRS Adjusted EBITDA will hereafter be referred to as Adjusted EBITDA loss or Aajusted EBITDA as applicable. Any estimates or forward-looking information or statements provided are accurate only as of the date of this call, and the company undertakes no obligation to publicly update any forward-looking information or statements or supply new information regarding the circumstances after the date of this call. Please also note that all references on this call reflect currency in CAD unless otherwise stated. With that, it's my pleasure to turn the call over to Oren Shuster, CEO of IM Cannabis. Oren, please go ahead.

[Oren Shuster, CEO at IM Cannabis]

Thank you, Anna. Good morning, everyone, and thank you for joining us today. While presenting the 2024 full year results in March, I focused on the progress we made internally, both strategically and operationally, the efficiencies and integration to build a solid right-sized foundation to deliver on in 2025. In Q1 2025, we can see in the group's financial results that we have hit our target. In Q1, IM Cannabis reached net profit with an 87% improvement in our gross margin versus Q1 2024. Our focus continues to be on execution, shifting our resources to where we see the biggest ROI and leaning into our integrated structure. In Q1, with our integrated supply chain, we launched a total of 12 new strengths in Germany, driving about EUR 3 million or 39% of our cannabis flower sales in Germany.

[Oren Shuster, CEO at IM Cannabis]

To put this into perspective, in the second half of 2024, we imported a total of 11 new strengths to Germany for an upside in sales of about 14% in Germany. In Q1 of 2025 alone, we have already exceeded the last six months of 2024. Needless to say, I'm very proud of the work the entire team, both in Israel and in Germany, put in to deliver these results. Moving on to Israel, we see that the shift in focus and resources towards the German market and supply delays impacted our Israeli business. While the Israeli revenue declined by 56% versus Q1 2024, our German business grew 569% versus Q1 2024, offsetting the revenue decline in Israel.

[Oren Shuster, CEO at IM Cannabis]

In addition, we are seeing that the cost-cutting measures produced by shifting our production facility in Israel in 2024 are flowing through to the financial results, leading to the increase in gross margin of 87% and an increase in gross profit of 94%. To sum up the first quarter of 2025, I'm delighted to see how the efficiencies and integration of the past two years is starting to be visible in our financial results. Our goal was for the group to be positive, which we achieved this quarter. Our target now is to continue to execute our strategy. I will now hand the call over to Uri, who will review our first quarter 2025 financial results. Uri?

[Uri Birenberg, CFO at IM Cannabis]

Thank you, Oren. Before reviewing our Q1 results, I would like to emphasize one of this quarter's milestones. The Adjusted EBITDA in Q1 2025 resulted in a profit of EUR 0.6 million compared to an adjusted EBITDA loss of EUR 2.2 million in Q1 2024, which is an improvement of almost EUR 3 million. The company achieved a net profit of approximately EUR 0.2 million. Our Q1 results were mainly impacted by the following points. The German region revenue in Q1 increased by 569% versus Q1 2024, and we continued with our expense reduction process, which resulted in a decrease in our operating expenses of approximately 56% versus Q1 2024. I will now take you through the overview of the Q1 2025 financial results for the company's operations. Revenues for Q1 2025 were EUR 12.5 million compared to EUR 12.1 million in Q1 2024, an increase of EUR 0.4 million or 4%.

[Uri Birenberg, CFO at IM Cannabis]

The increase is mainly attributed to the accelerated growth in Germany, with an increase in revenue of EUR 6.6 million and decreased revenue in Israel of EUR 6.1 million net. The decrease is attributed to the Oranim deal cancellation, which resulted in a decrease in revenue of approximately EUR 3.5 million compared to Q1 2024. Germany's share of total revenue in Q1 2025 has significantly increased compared to the corresponding period in 2024 to 62%. This increase has had a considerable impact, reflected in a higher average price due to favorable market conditions and growing demand. The cost of revenue for Q1 2025 were EUR 9.1 million compared to EUR 10.3 million in Q1 2024, a decrease of EUR 1.2 million or 12%. This is mainly due to the EUR 0.6 million slow inventory clearing in Q1 2024 and other expenses decreased in Q1 2025 of about EUR 0.6 million net.

[Uri Birenberg, CFO at IM Cannabis]

Gross profit for Q1 2025 was EUR 3.4 million compared to EUR 1.8 million in Q1 2024, an increase of EUR 1.6 million or 94%. G&A expenses for Q1 2025 were EUR 2 million compared to EUR 2.3 million in Q1 2024, a decrease of EUR 0.3 million or 14%. Selling and marketing expenses for Q1 2025 were EUR 1.3 million compared to EUR 2.3 million in Q1 2024, a decrease of EUR 1 million or 44%. The decrease is mainly attributed to our NIM revoked agreement of approximately EUR 0.8 million. Total operating expenses for Q1 2025 were EUR 3.3 million compared to EUR 7.4 million in Q1 2024, a decrease of EUR 4.1 million or 56%. Operating expenses ratio for Q1 2025 was 26% versus 77%, excluding the one-time expense outcome of our NIM deal cancellation for Q1 2024, representing an increased efficiency of about 66%. The efficiency ratio improvement results from decreased operational cost and increased revenue.

[Uri Birenberg, CFO at IM Cannabis]

EBITDA for Q1 2025 were EUR 0.6 million profit compared to loss of EUR 5 million in Q1 2024, an increase of EUR 5.6 million. Net profit for Q1 2025 was EUR 0.2 million compared to loss of EUR 6 million in Q1 2024, an increase of EUR 6.2 million. Diluted income per share for Q1 2025 was $0.09 compared to a loss of $2.52 per share in Q1 2024. As of the balance sheet, cash and cash equivalents of March 31st, 2025, were EUR 1.4 million compared to EUR 0.9 million on December 31st, 2024. Total assets as of March 31st, 2025, were EUR 44,934 compared to EUR 39,188 as of December 31st, 2024, representing an increase of EUR 5,746 or 15%. The increase is mainly due to an increase of EUR 2,850 in trade receivables, EUR 2,218 in inventory, EUR 1,031 in advance to suppliers.

[Uri Birenberg, CFO at IM Cannabis]

Total liabilities as of March 31st, 2025, were EUR 41,761 compared to EUR 36,042 as of December 31st, 2024, representing an increase of EUR 5,719 or 16%. The company plans to finance its operation from its existing and future working capital resources, as well as from its available credit facilities, and will continue to evaluate additional sources of capital and financing as needed. I would now like to turn the call back to you, Oren, for closing remarks. Oren?

[Uri Birenberg, CFO at IM Cannabis]

Thank you. To sum up Q1 2025, I'm delighted to see that the progress we have made internally, both strategically and operationally, is starting to impact the group's financial results directly. As of this quarter, we are profitable. I will now hand the call over to the operator to begin our question and answer session. Operator?

[Operator]

Thank you. To ask a question, please raise your hand using your mobile or desktop application or press star nine on your telephone keypad and wait for your name to be announced. We have our first question from Oscar.

[Operator]

Yes, hello. Hi. My question is, why is it important to, how do I say this, for the upcoming meeting of accepting the 25% of the new company? Why is that important given the given time of straight capital? Why is that, yeah, why is that important the upcoming meeting and being approved of us approving the 25% ownership of Focus? Yeah, why is that important at the moment right now? Thank you.

[Oren Shuster, CEO at IM Cannabis]

It's something that we are working on for quite some time on the regulative side, and it just happened now, but it's a long process. Also, Uri, I don't know if you want to relate to that.

[Uri Birenberg, CFO at IM Cannabis]

Yeah, I will take it. Basically, since we have a structure of companies, there are all kinds of balances that we want to clear between companies and to move them from, let's call it, long-term loan to investment as equity. According to tax regulations, in order to do it in our country, you're supposed to hold 100% of the, at least for the Focus company. Based on advice we received, the best way of doing it without getting into troubles of concerning it as revenue for tax purposes and those kinds of acts from the tax authorities, we must hold 100% of the Focus shares.

[Uri Birenberg, CFO at IM Cannabis]

We had to make some kind of a deal and use external valuation for the value of Focus for the rest of the 26% so we'd be able to acquire it and to be able to protect the company from a tax perspective.

[Uri Birenberg, CFO at IM Cannabis]

Okay, thank you.

[Oren Shuster, CEO at IM Cannabis]

Thank you.

[Operator]

To ask a question, please raise your hand using your mobile or desktop application and wait for your name to be announced. There are no further questions.

[Oren Shuster, CEO at IM Cannabis]

Thank you, operator, and thank you all for joining our call today.

Participants

Executives

• Anna Taranko, Head of Investor Relations
• Uri Birenberg, CFO
• Oren Shuster, CEO

Analysts

• Analyst